Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in High-Risk CLL (CLLM1)
NCT01556776Phase 3Completed
- Sponsor
- German CLL Study Group
- Start
- Jul 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia (CLL) comparing Lenalidomide with Placebo (2 arms). Primary endpoint: Progression-free survival up to 6 years. Started Jul 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01556776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556776.